Opyl (ASX:OPL) has appointed Dr. Hugo Stephenson, a leading expert in global clinical trials and health technology, as an advisor to its board.
Only says Dr. Stephenson has experience in founding successful businesses in the clinical trials industry, like DrugDev and MediGuard.
Opyl aims to use artificial intelligence to improve clinical trials and is working to accelerate the growth of Opin and monetise the TrialKey technology platform.